Balancing personalized medicine and personalized care

Academic Medicine

Volumn 88, Issue 3, 2013, Pages 309-313

  Cornetta, Kenneth ^a   Brown, Candy Gunther ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874949235     PISSN: 10402446     EISSN: 1938808X     Source Type: Journal    
DOI: 10.1097/ACM.0b013e3182806345     Document Type: Review

References (55)

1. Chan IS, Ginsburg GS. Personalized medicine: Progress and promise. Annu Rev Genomics Hum Genet. 2011;12:217-244.
2. Dworkin RW. Science, faith, and alternative medicine. Policy Rev. 2001;108:3-18.
3. Herper M. Not quite the $1,000 genome but maybe close enough. Forbes. January 10, 2012. http://www.forbes.com/sites/matthewherper/2012/01/10/ not-quite-the-1000-genome-but-maybe-close-enough/. Accessed December 31, 2012.
4. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208-1215.
5. Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA. 2011;305:1577-1584.
6. Link DC, Schuettpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through wholegenome sequencing of a patient with therapyrelated AML. JAMA. 2011;305:1568-1576.
7. Food and Drug Administration. FDA approves updated warfarin (Coumadin) prescribing information. http://www. fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108967.htm. Accessed November 11, 2012.
8. Robins Wahlin TB. To know or not to know: A review of behaviour and suicidal ideation in preclinical Huntington's disease. Patient Educ Couns. 2007;65:279-287.
9. Susswein LR, Skrzynia C, Lange LA, Booker JK, Graham ML 3rd, Evans JP. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer. J Clin Oncol. 2008;26:32-36.
10. Schwartz MD, Hughes C, Roth J, et al. Spiritual faith and genetic testing decisions among high-risk breast cancer probands. Cancer Epidemiol Biomarkers Prev. 2000;9:381-385.
11. Kash KM, Holland JC, Halper MS, Miller DG. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst. 1992;84: 24-30.
12. McDaniel SH. The psychotherapy of genetics. Fam Process. 2005;44:25-44.
13. Etchegary H, Perrier C. Information processing in the context of genetic risk: Implications for genetic-risk communication. J Genet Couns. 2007;16:419-432.
14. Hughes RA. The death of children by faith-based medical neglect. J Law Relig. 2004-2005;20:247-265.
15. Asser SM, Swan R. Child fatalities from religion-motivated medical neglect. Pediatrics. 1998;101(4 pt 1):625-629.
16. Dose A. Government endorsement of living on a prayer. Religious exemptions from the duty to provide medical treatment for children. J Leg Med. 2009;30:515-528.
17. Pew Forum on Religious and Public Life. Religious Beliefs and Practices: Diverse and Politically Relevant. June2008. Washington, DC: Pew Forum on Religious and Public Life.
18. Jewish Theological Seminary, Louis Finkelstein Institute of Religious and Social Studies. Evolution vs. Intelligent Design. http://www.jtsa.edu/JTS-in- Your-Community/Louis-Finkelstein-Institute-for-Religious-and-Social-Studies/ Public-Interest-Surveys/Evolution-vs-Intelligent-Design.xml. Accessed November 11, 2012.
19. Noll M. American Evangelical Christianity: An Introduction. Malden, Mass: Blackwell; 2000.
20. Evans JH. Religious belief, perceptions of human suffering, and support for reproductive genetic technology. J Health Polit Policy Law. 2006;31:1047-1074.
21. Brown CG. Testing Prayer: Science and Healing. Cambridge, Mass: Harvard University Press; 2012.
22. Pear R. Passions flare as house debates birth control rule. N Y Times. February 16, 2012. http://www.nytimes.com/2012/02/17/us/politics/birth-control- coverage-rule-debatedat-house-hearing.html?ref=contraception. Accessed November 11, 2012.
23. Annas GJ. "Culture of life" politics at the bedside-The case of Terri Schiavo. N Engl J Med. 2005;352:1710-1715.
24. Genetic Information Nondiscrimination Act of 2008. Congress of the U. S. of America. H.R. 493.
25. Hughes V. When patients march in. Nat Biotechnol. 2010;28:1145-1148.
26. Coelho T. A patient advocate's perspective on patient-centered comparative effectiveness research. Health Aff (Milwood). 2010;29:1885-1890.
27. Gallup G. Religion in America. Princeton, NJ: Princeton Religion Research Center; 1990.
28. Wallis C. Faith and healing. Time. June 24, 1996:58-63.
29. Fortin AH, Barnett KG. STUDENTJAMA. Medical school curricula in spirituality and medicine. JAMA. 2004;291:2883.
30. Puchalski CM. Spirituality and medicine: Curricula in medical education. J Cancer Educ. 2006;21:14-18.
31. Neely D, Minford EJ. Current status of teaching on spirituality in UK medical schools. Med Educ. 2008;42:176-182.
32. Bell D, Harbinson M, Toman G, Crawford V, Cunningham H. Wholeness of healing: An innovative student-selected component introducing United Kingdom medical students to the spiritual dimension in healthcare. South Med J. 2010;103:1204-1209.
33. Brokaw JJ, Tunnicliff G, Raess BU, Saxon DW. The teaching of complementary and alternative medicine in U.S. medical schools: A survey of course directors. Acad Med. 2002;77:876-881.
34. Society of General Internal Medicine. Position Statement on CAM Education. http://www.sgim.org/file%20library/sgim/communities/education/ resources/sgim-cam-statement-7-5-08.pdf. Accessed November 11, 2012.
35. Accreditation Council on Graduate Medical Education. Hospice and Palliative Medicine Core Competencies, Version 2.3, September2009. http://www.acgme. org/acgmeweb/Portals/0/PFAssets/ProgramRequirements/540- hospice-and-palliative-medicine-companion-09-2009. pdf. Accessed November 11, 2012.
36. Accreditation Council on Graduate Medical Education. ACGME Program Requirements for Graduate Medical Education in Psychiatry. http://www. acgme.org/acgmeweb/Portals/0/PFAssets/ProgramRequirements/400-psychiatry- 07012007-u04122008.pdf. Accessed November 11, 2012.
37. Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genet Med. 2011;13:349-355.
38. Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: Implications for drug development and global health. Nat Rev Genet. 2005;6:241-246.
39. Need AC, Goldstein DB. Next generation disparities in human genomics: Concerns and remedies. Trends Genet. 2009;25: 489-494.
40. Gurwitz D, Lunshof JE, Dedoussis G, et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J. 2005;5: 221-225.
41. Higgs JE, Andrews J, Gurwitz D, Payne K, Newman W. Pharmacogenetics education in British medical schools. Genomic Med. 2008;2:101-105.
42. Green JS, O'Brien TJ, Chiappinelli VA, Harralson AF. Pharmacogenomics instruction in US and Canadian medical schools: Implications for personalized medicine. Pharmacogenomics. 2010;11: 1331-1340.
43. Salari K, Pizzo PA, Prober CG. Commentary: To genotype or not to genotype? Addressing the debate through the development of a genomics and personalized medicine curriculum. Acad Med. 2011;86:925-927.
44. Walt DR, Kuhlik A, Epstein SK, et al. Lessons learned from the introduction of personalized genotyping into a medical school curriculum. Genet Med. 2011;13: 63-66.
45. Springer JA, Iannotti NV, Kane MD, Haynes K, Sprague JE. Instructional design and assessment. Pharmacogenomics training using an instructional software system. Am J Pharm Educ. 2011;75:1-8.
46. Haspel RL, Arnaout R, Briere L, et al. A call to action: Training pathology residents in genomics and personalized medicine. Am J Clin Pathol. 2010;133:832-834.
47. Gurwitz D, Weizman A, Rehavi M. Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci. 2003;24:122-125.
48. Pollack A. F.D.A. faults companies on unapproved genetic tests. N Y Times. June 11, 2010. http://www.nytimes. com/2010/06/12/health/12genome. html?scp=1&sq=polack%20genetic%20 tests&st=cse. Accessed November 11, 2012.
49. Imai K, Kricka LJ, Fortina P. Concordance study of 3 direct-to-consumer genetictesting services. Clin Chem. 2011;57: 518-521.
50. Lippi G, Favaloro EJ, Plebani M. Directto-consumer testing: More risks than opportunities. Int J Clin Pract. 2011;65: 1221-1229.
51. Hudson K, Javitt G, Burke W, Byers P. ASHG statement on direct-to-consumer genetic testing in the united states. Am J Hum Genet. 2007;81:635-637.
52. National Human Genome Research Institute. Informed Consent. http://www.genome. gov/10002332. Accessed November 11, 2012.
53. American Academy of Pediatrics Committee on Bioethics. Ethical issues with genetic testing in pediatrics. Pediatrics. 2001;107:1451-1455.
54. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol. 2003;21: 2397-2406.
55. Flockhart DA, O'Kane D, Williams MS, et al; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10:139-150.